Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 53-58

  Kozielska, Magdalena ^a,e   Pilla Reddy, Venkatesh ^a,f   Johnson, Martin ^a,f   De Ridder, Filip ^b   Vermeulen, An ^b   Liu, Jing ^c   Groothuis, Geny M M ^a   Danhof, Meindert ^d   Proost, Johannes H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c PFIZER INC   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

^e HANZE UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antipsychotics; LOCF; MMRM; PANSS; PANSS subscales; PKPD

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

ARTICLE; DRUG EFFECT; DRUG RESPONSE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; HUMANS; MODELS, STATISTICAL; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84875937231     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.01.022     Document Type: Article

References (24)

1. Beal S.S. NONMEM User's Guides 2010, Icon Development Solutions, Ellicott City, Maryland, USA.
2. Davis J.M., Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J. Clin. Psychiatry 2001, 62(10):757-771.
3. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004, 24(2):192-208.
4. Jonsson E.N., Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 1999, 58(1):51-64.
5. Kane J.M., Correll C.U. Past and present progress in the pharmacologic treatment of schizophrenia. J. Clin. Psychiatry 2010, 71(9):1115-1124.
6. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrom Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
7. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the Positive and Negative Syndrom Scale for schizophrenics. Psychiatry Res. 1988, 23(1):99-110.
8. Keizer R.J., van Benten M., Beijnen J.H., Schellens J.H.M., Huitema A.D.R. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput. Methods Programs Biomed. 2011, 101(1):72-79.
9. Lader M. Rating scales in schizophrenia - a review of their usefulness for assessing atypical antipsychotics. CNS Drugs 2000, 14(1):23-32.
10. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm. Stat. 2008, 7(2):93-106.
11. Leucht S., Heres S., Hamann J., Kane J.M. Methodological issues in current antipsychotic drug trials. Schizophr. Bull. 2008, 34(2):275-285.
12. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 2001, 11(1-2):9-21.
13. Mallinckrodt C.H., Watkin J.G., Molenberghs G., Carroll R.J. Choice of the primary analysis in longitudinal clinical trials. Pharm. Stat. 2004, 3(3):161-169.
14. Pilla Reddy, V., 2012. Translational PKPD modelling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety. PhD Thesis, University of Groningen, the Netherlands. http://dissertations.ub.rug.nl/faculties/science/2012/v.p.reddy/.
15. Pilla Reddy V., Kozielska M., Johnson M., Suleiman A.A., Vermeulen A., de Greef R., Liu J., Groothuis G.M.M., Danhof M., Proost J.H. Modelling and simulation of the positive and negative syndrome scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin. Pharmacokinet. 2012, 51:261-275.
16. Powell J.R., Gobburu J.V.S. Pharmacometrics at FDA: evolution and impact on decisions. Clin. Pharmacol. Ther. 2007, 82(1):97-102.
17. R Development Core Team R: A Language and Environment for Statistical Computing 2011, R Foundation for Statistical Computing, Vienna, Austria, (http://www.R-project.org).
18. Santen G., Gomeni R., Danhof M., Della Pasqua O. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J. Psychiatr. Res. 2008, 42(12):1000-1009.
19. Santor D.A., Ascher-Svanum H., Lindenmayer J.-P., Obenchain R.L. Item response analysis of the Positive and Negative Syndrome Scale. BMC Psychiatry 2007, 7:66. 10.1186/1471-1244X-1187-1166.
20. Sheiner L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 1997, 61(3):275-291.
21. Siddiqui O., Hung H.M.J., O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat. 2009, 19(2):227-246.
22. van der Gaag M., Cuijpers A., Hoffman T., Remijsen M., Hijman R., de Haan L., van Meijel B., van Harten P.N., Valmaggia L., de Hert M., Wiersma D. The five-factor model of the Positive and Negative Syndrome Scale - I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr. Res. 2006, 85(1-3):273-279.
23. Vermeulen A., Piotrovsky V., Ludwig E.A. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J. Pharmacokinet. Pharmacodyn. 2007, 34(2):183-206.
24. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137(1-3):246-250.